I-AASraw ivelisa i-Cannabidiol (CBD) ipowder kunye ne-Hemp ebalulekileyo yeoyile ngobuninzi!

Iziyobisi ezichasene nomhlaza Acalabrutinib

 

  1. I-Acalabrutinib yangasemva
  2. Uphengululo lweAcalabrutinib
  3. Unyango lwe-Acalabrutinib (Isetyenziselwa)
  4. Indlela yeActalabrutinib yokuSebenza
  5. Zithini iziphumo ebezingalindelekanga zeAcalabrutinib?
  6. I-Acalabrutinib VS Ibrutinib
  7. Uphando: I-Acalabrutinib kunyango lwe-lymphocytic leukemia (CLL)

 

I-Acalabrutinib yangasemva

Ukuza kuthi ga ngoku, i-acalabrutinib isetyenzisiwe kwizilingo ezifunda unyango lwe-B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, kunye neHodgkin Lymphoma, phakathi kwabanye.

Ukusukela nge-31 ka-Okthobha ka-2017 i-FDA ivume i-Astra Zeneca ngomlomo olawulwa ngomlomo (acalabrutinib). Le Bruton Tyrosine Kinase (BTK) inhibitor ibonakalise unyango lwe-lymphocytic leukemia, i-lymphocytic lymphoma encinci, kunye nezigulana zabantu abadala abane-Mantle Cell Lymphoma (MCL) esele befumene unyango olunye ngaphambili.

Kwaziwa njenge I-ACP-196I-acalabrutinib ikwajongwa njengesizukulwane sesibini se-BTK inhibitor kuba yayiyilelwe ukuba ibenamandla kwaye ikhethe ngaphezu kwe-ibrutinib, kulindeleke ukuba ibonakalise iziphumo ebezingalindelekanga ezimbalwa ngenxa yokuncitshiswa kweempawu zokujolisa kwiithagethi ngaphandle kwe-BTK.

Nangona kunjalo, i-acalabrutinib yamkelwe phantsi kwendlela yokuvunywa okukhawulezileyo ye-FDA, esekwe kwinqanaba lokuphendula lilonke kunye nolwamkelo lwangaphambili lwamayeza anyanga iimeko ezinobuzaza okanye / kwaye azalisa imfuno yezonyango engafezekiswanga esekwe kwisiphelo sesivumelwano. Ukuqhubeka kokuvunywa kwesalathiso esamkelweyo ngoku se-acalabrutinib kunokubakho kuxhomekeko oluqhubekayo kunye nenkcazo yesibonelelo seklinikhi kwizilingo zokudibanisa.

Ngaphaya koko, i-FDA inike eli nyango ukuHlola okuPhambili kunye nokuchongwa kweNyango yokuNyanga. Ikwafumene ukubizwa kwe-Orphan Drug, ebonelela ngenkuthazo ekuncedeni nasekukhuthazeni uphuhliso lweziyobisi kwizifo ezinqabileyo. Ngeli xesha, ngaphezulu kweemvavanyo zeklinikhi ezingama-35 kumazwe angama-40 ngaphezulu kwezigulana ezingama-2500 ziyaqhubeka okanye zigqityiwe ngokubhekisele kuphando oluqhubekayo ekuqondeni okungcono kunye nokwandisa ukusetyenziswa kwezonyango ze-acalabrutinib 5.

 

Acalabrutinib Reviews

I-Acalabrutinib (i-CAS:1420477-60-6), Ithengiswa phantsi kwegama lokuthengisa laseCalquence® e-US nase Canada, sisizukulwana sesibini esincinci se-molecule inhibitor ye-Bruton's tyrosine kinase (BTK). Kulawulo lomlomo, i-acalabrutinib ibopha kwaye ingathinteleki kuthintele umsebenzi we-BTK othintela zombini ukusebenza kwe-B kunye ne-B-cell-mediated signaling. Eli nyathelo likhokelela kuthintelo lokukhula kweeseli ezinobungozi ze-BTK. I-BTK iyimfuneko ekutyikityweni kweseli ye-B, idlala indima ephambili kukuvuthwa kweeseli ze-B, kwaye igqithisiwe kakhulu kwinani le-B-cell malignancies, kubandakanya ne-CLL / SLL. Inkcazo ye-BTK kwiiseli zethumba inxulunyaniswa nokwanda okwandayo kunye nokusinda. Njengesithinteli sesibini se-BTK inhibitor, i-acalabrutinib yayilelwe ukwandisa isiphumo kwi-BTK kunye nokunciphisa umsebenzi ekujoliswe kuwo kwi-TEC (iTec Protein Tyrosine Kinase), i-EGFR (i-epidermal growth factor receptor), kunye ne-ITK (interleukin-2-inducible T- iseli kinase). Isizukulwana sokuqala se-BTK inhibitor, ibrutinib (Imbruvica), iswele oku kubangela imeko ephezulu yeziphumo ezibi. Ukongeza kwi-CLL / SLL, i-acalabrutinib ivunyelwe iMantle Cell Lymphoma (MCL). Uluhlu lweZikhokelo zeCancer Cancer (NCCN) uluhlu lwe-acalabrutinib kunye okanye ngaphandle kwe-obinituzumab njengonyango lokuqala lwe-CLL / SLL kunye nokusetyenziswa ngokufanelekileyo ekubuyiseleni kwakhona okanye ekuphikiseni (R / R) CLL.

 

Acalabrutinib Unyango (olusetyenziselwa)

I-Acalabrutinib isetyenziselwa ukunyanga abantu abane-mantle cell lymphoma (i-MCL; umhlaza okhula ngokukhawuleza oqala kwiiseli zamasosha amajoni omzimba) esele zinyangiwe ngamanye amayeza e-chemotherapy.

I-Acalabrutinib isetyenziswa yodwa okanye nge-obinutuzumab (Gazyva) ukunyanga Leukemia engapheliyo ye-lymphocytic (CLL; uhlobo lomhlaza oqala kwiiseli ezimhlophe zegazi) kunye ne-lymphocytic lymphoma encinci (i-SLL: uhlobo umhlaza oko kuqala kwiiseli ezimhlophe zegazi).

I-Acalabrutinib ikwiklasi yamayeza abizwa ngokuba yi-kinase inhibitors. Isebenza ngokuthintela isenzo seprotein engaqhelekanga ebonisa iiseli zomhlaza ukuba zande. Oku kunceda ukunqanda ukusasazeka kweeseli zomhlaza.

 

Acalabrutinib Indlela Of Action

I-Mantle Cell Lymphoma (MCL) luhlobo olunqabileyo kodwa olunobundlongondlongo lwe-B-cell non-Hodgkin lymphoma (NHL) enesifo esibi. Emva koko, ukubuyela umva kuyinto eqhelekileyo kwizigulana ze-MCL kwaye ekugqibeleni kubonisa ukuqhubela phambili kwesifo.

I-Lymphoma yenzeka xa amajoni omzimba e-lymphocyte ekhula kwaye ephindaphindeka ngokungalawuleki. Ii-lymphocyte ezinomhlaza zinokuhamba ziye kwiindawo ezininzi zomzimba, kubandakanya ii-lymph node, udakada, umongo wethambo, igazi, kunye namanye amalungu apho zinokuphindaphindeka zenze ubunzima (obubizwa ngokuba yithumba). Olunye lweentlobo eziphambili zeelymphocyte ezinokuthi zikhule zibe ngumhlaza wesifo somhlaza zii-B-lymphocyte zomzimba (ii-B-seli) zomzimba.

I-Bruton Tyrosine Kinase (BTK) yimolekyuli ebonisa i-B-cell antigen receptor kunye ne-cytokine receptor pathways. Olo phawu lwe-BTK lubangela ukwenziwa kweendlela eziyimfuneko ukwanda kweeseli ze-B, ukurhweba ngabantu ngokungekho mthethweni, i-chemotaxis, kunye nokubambelela.

I-Acalabrutinib yincinci ye-molecule inhibitor ye-BTK. Zombini i-acalabrutinib kunye ne-metabolite yayo esebenzayo, i-ACP-5862, yenza isenzo sokudibanisa intsalela kunye ne-cysteine ​​residue (Cys481) kwindawo esebenzayo ye-BTK, ekhokelela kuthintelo lomsebenzi we-BTK enzymatic. Ngenxa yoko, i-acalabrutinib inqanda ukusebenza kwe-BTK-Mediated kwe-riverstream. ukutyikitya iiproteni ze-CD86 kunye ne-CD69, ethi ekugqibeleni ithintele ukwanda okungalunganga kwe-B kunye nokuphila.

Ngelixa ibrutinib iqatshelwa njenge-in-class yokuqala ye-BTK inhibitor, i-acalabrutinib ithathwa njengesizukulwane sesibini se-BTK inhibitor ikakhulu kuba ibonisa ukukhetha okuphezulu kunye nokuthintela imisebenzi ekujoliswe kuyo ye-BTK ngelixa ine-IC50 enkulu kakhulu okanye kungenjalo akukho sithintelo imisebenzi ye-kinase ye-ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, kunye ne-YES1.

Ngokwenyani, i-acalabrutinib yenzelwe ukuba ibenamandla ngakumbi kwaye ikhethe ngaphezu kwe-ibrutinib, ngalo lonke eli xesha ibonisa iziphumo ezibi ezimbalwa-kwithiyori- ngenxa yokuncitshiswa kwesiyobisi kwiziphumo ezijolise kuzo.

 

Zithini iziphumo ebezingalindelekanga zeAcalabrutinib?

I-Acalabrutinib inokubangela iziphumo ebezingalindelekanga ezibi, kubandakanya:

Usulelo olukhulu lunokwenzeka ngexesha lonyango nge-Acalabrutinib kwaye lunokukhokelela ekufeni. Umboneleli wakho wezempilo unokuyalela amayeza athile ukuba unobungozi obonyukayo bokufumana usulelo. Xelela umboneleli wakho wezempilo kwangoko ukuba unayo nayiphi na imiqondiso okanye iimpawu zosulelo, kubandakanya umkhuhlane, ukugodola, okanye iimpawu ezinje ngomkhuhlane.

Iingxaki zokuphuma kwegazi (ukuphuma kwegazi) zinokwenzeka ngexesha lonyango nge-Acalabrutinib kwaye zinokuba nzulu kwaye zingakhokelela ekufeni. Umngcipheko wokuphuma kwegazi unokunyuka xa uthatha iyeza elincinci legazi. Xelela umboneleli wakho wezempilo ukuba ngaba unayo nayiphi na imiqondiso okanye iimpawu zokopha, kubandakanya igazi kwizitulo zakho okanye ilindle elimnyama (lijongeka njengetar), ipinki okanye umchamo omdaka ngombala, ukopha okungalindelekanga okanye ukopha okunzima okanye awukwazi ukulawula, gabha igazi okanye ugabhe oko ijongeka ngathi yindawo yekofu, khohlela igazi okanye amahlwili egazi, isiyezi, ubuthathaka, ukudideka, utshintsho kwintetho yakho, intloko ebuhlungu ehlala ixesha elide, okanye ukugruzuka okanye umbala obomvu okanye omfusa

Ukuncipha kubalo lweeseli zegazi. Ukuhla kwegazi (iiseli ezimhlophe zegazi, iiplatelets, kunye neeseli ezibomvu zegazi) ziqhelekile nge-Acalabrutinib, kodwa kunokuba nzima. Umboneleli wakho wezempilo kufuneka enze uvavanyo lwegazi ukujonga ukubala kwegazi kwakho rhoqo ngexesha lonyango kunye neAcalabrutinib.

Umhlaza wesibini wokuqala. Umhlaza omtsha wenzekile ebantwini ngexesha lonyango nge-Acalabrutinib, kubandakanya umhlaza wolusu okanye amanye amalungu. Umboneleli wakho wezempilo uya kukujonga umhlaza wolusu ngexesha lonyango ngeAcalabrutinib. Sebenzisa ukukhuselwa lilanga xa ungaphandle elangeni.

Iingxaki zesingqisho senhliziyo (i-fibrillation ye-atrial kunye ne-atrial flutter) zenzekile kubantu abaphathwe nge-Acalabrutinib. Xelela umboneleli wakho wezononophelo lwempilo ukuba unayo nayiphi na le miqondiso okanye iimpawu zilandelayo: ukukhawuleza kwentliziyo okanye okungaqhelekanga, isiyezi, ukuziva utyhafile, ukungonwabi esifubeni, okanye ukuphefumla kancinci

Iziphumo eziqhelekileyo ezichaphazela i-Acalabrutinib zibandakanya intloko ebuhlungu, urhudo, iintlungu zemisipha kunye nokudibana, usulelo lokuphefumla oluphezulu kunye nokugruzuka.

Ayizizo zonke iziphumo ebezingalindelekanga ezinokubakho zeAcalabrutinib. Shayela ugqirha wakho malunga neengcebiso. Unokuxela iziphumo ebezingalindelekanga kwi-FDA ngo-1-800-FDA-1088.

 

Acalabrutinib

 

 

I-Acalabrutinib VS Ibrutinib

I-BTK idlala indima ephambili kwi-B-cell receptor signaling pathway; I-acalabrutinib ibopha ngokungenakuphikwa kwi-BTK kwaye inqanda umsebenzi wayo. Iyeza liyilelwe njenge-BTK inhibitor enokukhetha ngakumbi, ukuzama ukunciphisa ezinye izinto ezinobungozi ezithintela unyango ezihlala zibonwa ibrutinib. NgokukaGqirha uBrown, "i-Acalabrutinib yeyona inhibitor ekhethiweyo kubantu abane-comorbidities, ngakumbi imiba yentliziyo."

Idatha yokusebenza kakuhle ibonakala ifana phakathi kwe-acalabrutinib kunye ne-ibrutinib, nangona ukulandelelwa kukude nge-ibrutinib, uGqirha Brown uqhubeke. Ke ngoko, umahluko ophambili phakathi kwamachiza lilele kwiprofayili yecala lesiphumo. Ibrutinib ithambekele ekubeni inyamezeleke ngakumbi kwizigulana ezindala kwaye inxulunyaniswa namazinga aphezulu e-atrial fibrillation kunye noxinzelelo lwegazi. "I-Acalabrutinib inyamezeleke ngcono [kune-ibrutinib], ke ndiyisebenzisa ngokukhethekileyo, ngakumbi kwizigulana zam ezindala, utshilo.

Ukuvunywa kwesiyobisi kwi-CLL, enikezwe ngo-Novemba ngo-2019, yayisekwe kwidatha yokhuseleko kunye nokusebenza ngokukuko kuvavanyo lwethutyana lwesilingo se-ELEVATE-TN sezigulana ezazingafakwanga unyango lwe-CLL kunye novavanyo lwe-ASCEND lwezigulana ezibuyileyo okanye ezithandabuzayo ze-CLL. Kuzo zombini izilingo, i-acalabrutinib ibonakalise ukusinda okungaphaya kokuqhubela phambili okungathelekiswa nonyango oluqhelekileyo, kunye neprofayili yokunyamezeleka. Kwilingo le-ELEVATE-TN, ngokukodwa, i-acalabrutinib idityaniswe ne-obinutuzumab kwaye njenge-monotherapy inciphise umngcipheko wokuqhubela phambili kwesifo okanye ukufa nge-90% kunye ne-80%, ngokwahlukeneyo.

"Ukunyamezeleka kuhlala kungumba kwindawo yangoku yonyango lwe-CLL, enokufuna unyango oluqhubekayo iminyaka emininzi," utshilo uJeff Sharman, MD, uMlawuli wezoPhando eWillamette Valley Cancer Iziko, uMlawuli wezoNyango kuPhando lweHematology ye-US Oncology Network, kunye nombhali okhokelayo wovavanyo lwe-ELEVATE-TN. "Kwilingo le-ELEVATE-TN kunye ne-ASCEND ngokuthelekisa [i-acalabrutinib] neerejimeni zonyango ezisetyenziswa ngokuqhelekileyo, [i-acalabrutinib] ibonakalise ukuphucuka okunentsingiselo ekliniki ekuqhubekeni kokungabikho kwezigulana kwiindawo ezininzi, ngelixa kugcinwa ukunyamezeleka kwayo kunye neprofayili yokhuseleko."

 

Uphando: Acalabrutinib Ekunyangeni Isifo se-lymphocytic leukemia (CLL) esingapheliyo  

(1) Isifo se-lymphocytic leukemia (CLL) esingapheliyo

Isifo se-lymphocytic leukemia (CLL), eyona leukemia yabantu abadala ixhaphakileyo, yiplonal neoplasm equlathe iiseli ezincinci ze-monomorphic ezincinci ezi-coexpress CD5 kunye ne-CD23. Imeko yonyango lwe-CLL itshintshe kakhulu kule minyaka idlulileyo. Iziyobisi ezijolise kwiiproteni kwi-B cell antigen receptor (BCR) yendlela, enje nge-ibrutinib, ibonakalise ukuphucula kwinkqubela phambili yasimahla kunye nokusinda ngokubanzi, kubandakanya nezigulana ezinesifo esisesichengeni. Nangona la machiza eyitshintshe iparadigm yonyango kwizigulana ezine-CLL, ukuvezwa kunyango kunye nokuqina kwe-ibrutinib kunokuthintelwa ngenxa yecala lesiphumo secala kunye neetyhefu ezinxulumene nonyango. I-Acalabrutinib, isizukulwana sesibini kunye nokukhetha ngakumbi i-Bruton's tyrosine kinase (BTK) inhibitor, yaphuhliswa ukwandisa ukusebenza ngempumelelo ngelixa kuncitshiswa iziganeko ezichaseneyo ne-ibrutinib ezichazwe ukuba zibe kwindawo yesibini yeziphumo ze-ibrutinib. Olu hlaziyo luza kushwankathela uphuhliso, uvavanyo lwaphambi konyango, kunye novavanyo oluphambili lweklinikhi olubonakalise ukusebenza kwe-acalabrutinib kunye neprofayili yetyhefu kwi-CLL.

 

(2) Izifundo zangaphambi kwe-Acalabrutinib kwi-CLL

Izifundo ezininzi zangaphambi kokubonisa zibonisa ukusebenza kwe-acalabrutinib kwi-BTK inhibition. Xa kuvavanywa igazi elipheleleyo lomntu, i-acalabrutinib yayine-BTK inhibition ye-equipotent xa kuthelekiswa ne-ibrutinib. Ibrutinib kwafunyaniswa ukuba ibangela ukwanda kweapoptosis yeeseli ze-CLL xa kuthelekiswa ne-acalabrutinib, enokuchazwa ziziphumo ekujolise kuzo ze-ibrutinib. I-Acalabrutinib yayinefuthe elincinci kwizisele ezinempilo ze-T ngenxa yokukhetha kwayo xa kuthelekiswa ne-ibrutinib.

Iziphumo ezichasene ne-tumor ze-acalabrutinib zavavanywa kwiimodeli ezimbini ze-murine ze-CLL: imodeli yokudluliselwa eyamkelekileyo ye-TCL1 kunye nemodeli ye-CLL yabantu. I-Acalabrutinib ibonakalisiwe ukuba inqanda ukusayina kwe-BCR kunye nonyango nge-acalabrutinib yayanyaniswa nokonyuka okubonakalayo ekusindeni xa kuthelekiswa neempuku ezinganyangekiyo (iintsuku ezingama-81 eziphakathi kweentsuku ezingama-59, p = 0.02). I-Acalabrutinib ikwabangele ukuncitshiswa okubonakalayo kwiiseli ezandayo kunye nomthwalo opheleleyo wepelen.

Ukusebenzisana kwe-Acalabrutinib kunye ne-anti-CD20 monoclonal antibodies kuye kwavavanywa. Ibrutinib inokuphazamisa iindlela ezininzi zesenzo se-anti-CD20 antibodies ethintela ngokukodwa i-cytotoxicity yeselfowni exhomekeke kulwahlulo kunye ne-phagocytosis enokuthi inciphise umphumo wayo wokuchasana nethumba. Ndafumanisa ukuba khange iphazamisane nezi nkqubo, kunokwenzeka ngenxa yeziphumo ebezingalindelekanga ezincinci ze-acalabrutinib. Nangona indibaniselwano ye-acalabrutinib kunye ne-anti-CD20 monoclonal antibody khange ifundwe kwimodeli ye-vivo, inqanaba lesibini le-2 kunye nesigaba Izifundo ezi-3 ziyaqhubeka okanye zigqityiwe ezibonisa ukusebenza kwe-acalabrutinib ngokudibanisa ne-anti-CD20 monoclonal antibody.

Olunye udibaniso lwe-acalabrutinib luye lwafundwa kwi-vitro nakwiimodeli ze vivo. I-Acalabrutinib idityaniswe ne-PI3Kdelta inhibitor (i-ACP-319) kwimodeli ye-murine ye-CLL kwaye yabonisa ukunciphisa okukhulu ukwanda kwethumba, ukusayina kwe-NF-KB kunye nokubonisa kwe-BCL-xL kunye ne-MCL-1 xa kuthelekiswa ne-monotherapy. Abangabhalisanga kuvavanyo lweklinikhi baphathwa nge-acalabrutinib kunye ne-venetoclax.Umdibaniso ubonakalisiwe ukonyusa i-apoptosis xa kuthelekiswa nelinye ichiza, ucebisa ubudlelwane obunxulumene ngokufanayo nobo babonwa nge-ibrutinib kunye ne-venetoclax. Uvavanyo olulandelayo lwe-vivo lubonakalise ukuhlala ixesha elide kwiimpuku eziphathwe ngazo zombini i-acalabrutinib kunye ne-venetoclax xa kuthelekiswa neziyobisi zodwa.

 

(3) izigqibo

Isishwankathelo, izifundo ezichaziweyo zibonisa ukuba i-acalabrutinib inokubaluleka kunyango lwe-CLL, zombini unyango lwe-naïve kunye nokubuyela umva kwakhona. Akucaci ukuba ukusebenza kuyalingana okanye kungaphezulu kwe-ibrutinib kwaye izifundo ziyaqhubeka kumzamo wokuqhubeka nokuthelekisa ezi arhente. Nangona iityhefu ezinxulunyaniswa ne-BTK ezinje ngokuphuma kwegazi okanye iminyhadala ye-atrial fibrillation ziziganeko ezenzeka rhoqo, acalabrutinib Ineprofayili eyahlukileyo ye-AE, ngakumbi intloko, efuna ukubekwa esweni ngononophelo kunye nobuchule kulawulo. Idatha evela kwizifundo eziqhubekayo zokuvavanya indibaniselwano ye-acalabrutinib iya kunceda ekuchazeni ngakumbi indima yayo kulawulo lwe-CLL. Okokugqibela, ngokuvunywa kwe-FDA, amava okwenyani nge-acalabrutinib aya kunceda ekuchazeni ngakumbi iprofayili yetyhefu.

 

isingqiniso

[1] Ulawulo lwezoKutya kunye noLawulo lweziyobisi. Iprojekthi yeOrbis: I-FDA ivuma i-acalabrutinib ye-CLL kunye ne-SLL. Iyafumaneka kwi-https: //www.fda.gov/drugs/resource-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll. Kufumaneka ngo-Apreli 29, 2020.

[2] USharman JP, uBanerji V, uFogliatto LM, et al. I-ELEVATE-TN: Isigaba sesi-3 sophando lwe-acalabrutinib edityaniswe ne-obinutuzumab okanye iyodwa vs i-obinutuzumab kunye ne-chlorambucil kwizigulana ezine-leukemia enganyangekiyo ye-lymphocytic. Igazi 2019; 134 (suppl 1): 31.

[3] Ukukhutshwa kweendaba ze-AstraZeneca. Ubungakanani obuvunyiweyo e-US kwizigulana zabantu abadala abane-lymphocytic leukemia. Iyafumaneka kwi-https: //www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. Kufumaneka ngo-Apreli 29, 2020.

[4] UGoede V, uFischer K, uBusch R, et al. I-Obinutuzumab kunye ne-chlorambucil kwizigulana ezine-CLL kunye neemeko ezikhoyo. N Engl J Med. Ngo-2014; 370 (12): 1101-1110. ikhonkco: 10.1056 / NEJMoa1313984.

[5] UParikh SA, uMuchtar E, uLaplant B, et al. Isifundo esingahleliwe sesigaba 2 ngokuthelekisa i-acalabrutinib kunye okanye ngaphandle kwe-obinutuzumab kunyango lwezigulana ezisengozini ephezulu ene-Chronic Lymphocytic Leukemia (CLL) okanye iLymphocytic Lymphoma (SLL) encinci. Igazi. 2019; 134 (Isongezelelo_1): 4306. ikhonkco: 10.1182 / blood-2019-123824.

[6] UCovey T, uGulranjani M, uCheung J, et al. Ukuvavanywa kwe-Pharmacodynamic ye-acalabrutinib kwizigulana ezibuyileyo / ezinqabileyo kunye nonyango ezingenasifo seLymphocytic Leukemia (CLL) kwisigaba se-1/2 ACE-CL-001. Igazi. 2017; 130 (Isongezo1): 1741. ikhonkco: 10.1182 / igazi.V130.Suppl_1.1741.1741.

[7] U-Byrd JC, uBrown JR, u-O'Brien S, et al. Ibrutinib xa ithelekiswa ne -atumumab kunyango lwe-lymphoid leukemia enganyangekiyo ngaphambili. N Engl J Med. Ngo-2014; 371 (3): 213-223. ikhonkco: 10.1056 / NEJMoa1400376.

[8] UWoyach JA, uBojnik E, uRuppert AS, et al. Umsebenzi weBruton's tyrosine kinase (BTK) ubalulekile kuphuhliso kunye nokwandiswa kwe-leukemia enganyangekiyo ye-lymphocytic (CLL). Igazi. Ngo-2014; 123 (8): 1207-1213. ikhonkco: 10.1182 / igazi-2013-07-515361.

[9] I-Chiorazzi N, Rai KR, Ferrarini M.I-lymphocytic leukemia engapheliyo. N Engl J Med. 2005; 352 (8): 804-815. ikhonkco: 10.1056 / NEJMra041720.

[10] Inkulumbuso ye-Barr, uRobak T, u-Owen C, et al. Ukusebenza okuzinzileyo kunye nokulandelelwa kweeklinikhi kunyango lokuqala lwe-ibrutinib kunyango kwizigulana ezindala ezine-lymphocytic leukemia engapheliyo: iziphumo ezandisiweyo zesigaba 3 kwi-RESONATE-2. I-Haematologica. 2018; 103 (9): 1502-1510. ikhonkco: 10.3324 / haematol.2018.192328.

[11] IHerman SEM, iMontraveta A, i-Niemann CU, okqhubekayo. I-Bruton Tyrosine Kinase (BTK) inhibitor ACP-196 ibonisa imisebenzi yeklinikhi kwiimodeli ezimbini zeempuku ze-lymphocytic leukemia engapheliyo. Igazi. 2015; 126 (23): 2920. ikhonkco: 10.1182 / igazi.V126.23.2920.2920.

 

 

1 azithandayo
46 Views

Ungathanda

Amagqabantshintshi zivaliwe.